帕尼培南倍他米隆与亚胺培南西司他丁分别治疗细菌感染的系统评价  

System Review on Panipenem-betamipron and Imipenem-cilastatin in Respective Treatment of Bacterial Infection

作　　者：祝各亮 李琴[1] ZHU Geliang LI Qin(Dept. of Emergency, Medical University, Shanghai 200003, Chin)

机构地区：[1]第二军医大学附属长征医院急救科,上海200003

出　　处：《中国医院用药评价与分析》2017年第4期529-533,共5页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:系统评价帕尼培南倍他米隆与亚胺培南西司他丁分别治疗细菌感染的有效性和安全性。方法:计算机检索截至2016年11月中国生物医学文献数据库(CBM)、维普(VIP)、中国期刊网全文数据库(CNKI)、美国全科医学文献数据库(MEDLINE)、生物医学与药理学文摘数据库(EMbase)、Cochrane临床试验数据库中关于帕尼培南倍他米隆与亚胺培南西司他丁治疗细菌感染的随机对照研究,对检索文献进行质量评价及筛选,采用Review Manager 5.3软件对最终纳入的研究进行文献荟萃(Meta)分析。结果:共纳入11项随机对照研究,合计1 176例患者。Meta分析结果显示,帕尼培南倍他米隆与亚胺培南西司他丁治疗细菌感染的治愈率(OR=1.15,95%CI=0.90~1.47,P=0.26)、有效率(OR=1.30,95%CI=0.89~1.91,P=0.17)、细菌清除率(OR=0.90,95%CI=0.62~1.31,P=0.59)、不良反应发生率(OR=0.70,95%CI=0.46~1.07,P=0.10)及中枢神经系统不良反应发生率(OR=0.36,95%CI=0.09~1.37,P=0.36)的差异均无统计学意义。结论:帕尼培南倍他米隆治疗细菌感染的有效性和安全性与亚胺培南西司他丁相仿,特别是在减少中枢神经系统不良事件方面并未显示出明显的优势。Changzheng Hospital Affiliated to the Second Military OBJECTIVE： To systematically review the effectiveness and safety of panipenem-betamipron and imipenem-cilastatin in respective treatment of bacterial infection. METHODS ： CBM, VIP, CNKI, MEDLINE, EMbase and Cochrane experimental data base were retrieved by computers to collect the randomized controlled trials of panipenem-betamipron and imipenem-cilastatin in treatment of bacterial infection till Nov. 2016, quality assessment and filtration were carried out and the data was analyzed with RevMan 5.3 software. RESULTS： Eleven randomized controlled trials were included, with 1 176 patients in total. There were no significant differences in the cure rate （OR = 1.15, 95% CI = 0. 90-1.47, P = 0.26）, effective rate （OR = 1.30, 95% CI = 0.89-1.91, P = 0. 17）, bacterial clearance rate（ OR = 0. 90, 95% CI = 0. 62-1.31, P = 0. 59） , incidence of adverse reactions （ OR = 0.70, 95% CI = 0. 46-1.07, P = 0. 10） and the incidence of adverse reaction in central nervous system （ OR = 0. 36, 95% CI = 0. 09-1.37, P = 0. 36） of panipenem-betamipron and imipenem-cilastatin in treatment of bacterial infection. CONCLUSIONS： There were no significant differences between panipenem-betamipron and imipenem-cilastatin on clinical efficacy and safety in treatment of bacterial infection. Especially showed no significant advantages in reducing the incidence of adverse reactions in central nervous system.

关 键 词：帕尼培南倍他米隆 亚胺培南西司他丁 细菌感染 荟萃分析 

分 类 号：R978.1[医药卫生—药品]